02082016Headline:

Philadelphia, Pennsylvania

HomePennsylvaniaPhiladelphia

    Heading
    • E-Cigarette Explosions Causing Burns & Other Injuries

      E-Cigarette Explosions Causing Burns & Other Injuries

      E-cigarettes and vaporizers seem to be all the rage right now for those seeking a “healthier alternative” to cigarettes. However, more and more studies are showing that E-cigarettes and vaporizers are not safe alternatives to regular cigarettes. And now, the […]

    • Google Accused of Spying on Students Using Chromebooks

      Google Accused of Spying on Students Using Chromebooks

      Google is under fire for collecting and data mining school children’s personal information, according to a complaint filed with the Federal Trade Commission (FTC) by the Electronic Frontier Foundation (EFF), a nonprofit advocacy group. “Google violated a legally binding agreement […]

    • Is a Xarelto Bleeding Antidote in Sight?

      Is a Xarelto Bleeding Antidote in Sight?

      Portola Pharmaceuticals has designed a treatment to reverse the effects of blood thinners Xarelto and Eliquis. The anti-anticoagulant came through in a pair of Phase III trials and is poised for final FDA submission. The treatment, andexanet alfa, works as […]

    • Penn State Hershey – Second Hospital to Discover NMT Infections

      Penn State Hershey – Second Hospital to Discover NMT Infections

      An estimated 2,300 patients at Penn State Milton S. Hershey Medical Center, received a warning letter that they may be at risk for a bacterial infection if they underwent open-heart surgery within the past four years. According to the news […]

    • Plaintiff Verdict of $1.75M in Risperdal Gynecomastia Suit

      Plaintiff Verdict of $1.75M in Risperdal Gynecomastia Suit

      A $1.75 million verdict was recently awarded in the third case against Janssen Pharmaceuticals of Johnson & Johnson for allegedly failing to warn patients of the risks of gynecomastia in connection with the antipsychotic drug Risperdal. Gynecomastia is the development […]

    • A New Xarelto Lawsuit Alleges Drug Caused Man’s Fatal Bleed

      A New Xarelto Lawsuit Alleges Drug Caused Man’s Fatal Bleed

      Sheller.com reports on another lawsuit filed in Vermont against the manufacturers of blood-thinning drug Xarelto. The suit was filed in Vermont federal court under case number 2:14-cv-00159-CR by the daughter of a man who died due to uncontrollable bleeding. The […]

    • Xarelto Lawsuit Alleges Drug Caused Gastrointestinal Bleeding

      Xarelto Lawsuit Alleges Drug Caused Gastrointestinal Bleeding

      Sheller.com reports on another lawsuit filed against manufacturers of the drug Xarelto, claiming that it has caused gastrointestinal bleeding. The lawsuit was filed by a woman from Ohio who claims that she was prescribed the drug to prevent strokes associated […]

    • Latest MDL Xarelto Lawsuit Count Reported At 1,700 Cases

      Latest MDL Xarelto Lawsuit Count Reported At 1,700 Cases

      Sheller.com reports that Xarelto mass tort litigation has significantly grown in recent months, with 400 lawsuits against the blood-thinner drug’s manufacturers filed in August. The cases have been consolidated to form MDL No. 2592, and are being overseen by the […]

    • Wellspan York Hospital Warns Heart Surgery Patients of Potential Infections 

      Wellspan York Hospital Warns Heart Surgery Patients of Potential Infections 

      Patients who underwent open-heart surgery at Wellspan York Hospital, in Pennsylvania, within the past four years may be at risk for a bacterial infection, according to hospital officials. To date, the infections may have contributed to four deaths. All four […]

    • FDA Updates Invokana Label, Includes Stronger Warnings

      FDA Updates Invokana Label, Includes Stronger Warnings

      The U.S. Food and Drug Administration (FDA) has strengthened the warning for the Type II diabetes drug canagliflozin (Invokana, Invokamet) to include the increased risk of bone fractures and added new information about decreased bone mineral density. In 2013, Invokana […]